With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Current health news highlights include Apollo Hospitals' AI investments to alleviate staff workload, Dr. Mehmet Oz's Medicare ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Health-care companies fell, but not by as much as the broad market, as traders sought out defensive sectors. Drugmaker Mallinckrodt struck a deal to buy rival Endo, one of the drug makers driven into ...

The global anorexiant market is set for significant expansion, with a projected compound annual growth rate (CAGR) of 5.1% over the forecast period, according to a recent study by Future Market ...

Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...

A UConn professor and researcher who 28 years ago discovered a gene for a protein that limits human muscle growth is closer than ever to having that work play a significant role in treating those with ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...

Kepler Cheuvreux upgraded Novo Nordisk (NVO) to Buy from Hold with a price target of DKK 630, down from DKK 715. The firm views the company’s ...

SIRUM and Governor Wes Moore announced a new partnership to expand medication access across the state of Maryland. SIRUM, the ...